Could blocking an androgen ( testosterone) receptor lead to a new way to treat an aggressive form of breast cancer?
That’s a question researchers at the Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) in Phoenix, Ariz are exploring. Preliminary results of a Mayo Clinic — TGen collaborative study show the androgen receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).
Barbara Pockaj, M.D., a surgical oncologist at the Mayo Clinic in Arizona, discusses the study findings and the next steps in research.
To find a healthcare professional, use HealthLynked. It is a first of its kind medical network built as a social ecosystem with a higher purpose – improving healthcare. Go to HealthLynked.com to learn more, sign up for free, connect with your doctor, find a new doctor, securely store and share your health information. Download our HealthLynked app available on Apple and Android devices.